Kit for evaluating effect of 131I on treating differentiated thyroid cancer
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- 润安医学科技(苏州)有限公司
- Publication Date
- 2021-04-13
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the field of molecular biology technology, in particular to a method for evaluating 131 I kit for treating differentiated thyroid cancer efficacy. Background technique
[0002] Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) account for more than 90% of thyroid cancers, because they retain the function of thyroid follicular epithelial cells to a certain extent, such as sodium The expression of iodide transporter (sodium iodide symporter, NIS), the ability of iodine uptake, the ability of secreting thyroglobulin (thyroglobulin, Tg), the growth mode dependent on thyroid-stimulating hormone (thyroid-stimulating hormone, TSH), etc. It is called differentiated thyroid cancer (differentiated thyroid cancer, DTC). The increased incidence of DTC, especially PTC, is the main factor leading to the increase in the incidence of thyroid cancer in recent years. 131 I treatment of differentiated thyroid cancer (DTC)...